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ABSTRACT: Introduction: The Cl. NPhys Trial 3 showed that
attributes of nerve conduction (NC) were without significant
intraobserver differences, although there were significant inter-
observer differences. Methods: Trial 4 tested whether use of
written instructions and pretrial agreement on techniques and
use of standard reference values, diagnostic percentile values,
or broader categorization of abnormality could reduce signifi-
cant interobserver disagreement and improve agreement
among clinical neurophysiologists. Results: The Trial 4 modifica-
tions markedly decreased, but did not eliminate, significant
interobserver differences of measured attributes of NC. Use of
standard reference values and defined percentile values of
abnormality decreased interobserver disagreement and
improved agreement of judgment of abnormality among evalua-
tors. Therefore, the same clinical neurophysiologist should per-
form repeat NCs of therapeutic trial patients. Conclusions:
Differences in interobserver judgment of abnormality decrease
with use of common standard reference values and a defined
percentile level of abnormality, providing a rationale for their
use in therapeutic trials and medical practice.
Muscle Nerve 50: 900–908, 2014
The need for the Cl. NPhys Trial 4 arose from
consideration of the results of Cl. NPhys 3.1 In
Trial 3, 4 expert clinical neurophysiologists and
their associate technologists evaluated 8 attributes
of nerve conduction (NC) of the leg on 2 consecu-
tive days in 24 masked patients without and with
diabetic polyneuropathy. Although their intraob-
server agreement was high and not significantly
different between days 1 and 2, statistically signifi-
cant interobserver differences, sometimes of some
magnitude, were observed for most attributes of
NCs tested. A similar result had been reported ear-
lier by clinical neurophysiologists at Johns Hop-
kins.2 Trial 4, similar in design to Cl. NPhys Trial
3, tests whether interobserver differences can be
improved or eliminated by standardization of
nerve conduction technique, use of common refer-
ence values, and setting abnormality at a given per-
centile value.
METHODS
Conduct of Cl. NPhys Trial 4. The design of Cl.
NPhys Trial 4 was similar to that of Trial 3 (same
clinical neurophysiologists, same or similar diabetic
patients without and with diabetic polyneuropathy,
assessment of the same 8 attributes of nerve con-
duction of the leg, masked evaluation of subjects,
and preconditions of testing). In Trial 3, no direc-
tions were provided on how to test or judge abnor-
mality of the 8 attributes of NC. In Trial 4, specific
testing routines and methods of assessment were
provided in a specially prepared syllabus and in a
training session.
The same clinical neurophysiologists who had
participated in Trial 3 performed the NC tests in
Trial 4. They came from 4 different North Ameri-
can medical centers (London, Ontario, Canada;
Baltimore, Maryland, USA; Ann Arbor, Michigan,
USA; and Rochester, Minnesota, USA). Rather
than have the 24 subjects travel from Rochester to
the other medical centers for their NC evaluations
on 2 consecutive days, we had the smaller group of
investigators travel to Rochester, which allowed for
a more rigorous and masked trial and a cost sav-
ings. Trial 4 patients without and with diabetic
polyneuropathy included patients from Trial 3;
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others were recruited from the Rochester Diabetic
Polyneuropathy Study, substituting for patients
who had died or who no longer agreed to partici-
pate. Two of the 24 patients failed “at the last
minute” to participate in Trial 4: 1 because he was
snowbound and the other due to intercurrent
illness.
Before Trial 4, examiners were sent a syllabus
(prepared by W.J.L.) that detailed the specific pro-
cedures for the NC studies. The syllabus included
descriptions of the requirements for the electro-
myographic (EMG) instrument; the equipment to
be used, including materials for skin preparation,
stimulating electrodes, and recording electrodes;
and the methods to standardize recording and
measurement of the attributes of NC to be eval-
uated. The NC attributes analyzed were: com-
pound muscle action potential (CMAP) recorded
with stimulation at the knee; nerve conduction
velocity (MNCV) calculated from the CMAPs
recorded with stimulation at the knee and ankle;
motor distal latency (MNDL) from the CMAP with
ankle stimulation; and sensory nerve action poten-
tial amplitude (SNAP) and sensory distal latency
(SNDL) from the sural SNAP with stimulation 14.0
cm proximal to the active recording electrode.
The 8 NC attributes evaluated were fibular and tib-
ial MNCV, CMAP, and MNDL, and sural SNAP
and SNDL.
The training syllabus and the clinical demon-
stration emphasized skin preparation; precise and
standard electrode placement of stimulating,
recording, and reference electrodes; techniques to
provide optimal stimulation; use of just supramaxi-
mal stimulation; recognition of anomalous innerva-
tion; description of averaging for certain studies;
and standard techniques to measure interelectrode
distances and marking of the evoked responses
(e.g., baseline to initial negative peak amplitude
measurements).
On the day before the start of Cl. NPhys 4,
investigators met to review the use of these stand-
ard NC techniques. One of us (W.J.L.) demon-
strated the specific technique to be followed. All
clinical neurophysiologists agreed to follow the
exact procedures and techniques outlined in the
syllabus. Standard EMG instruments [2 Nicolet
EDX Viking (Middleton, Wisconsin) and 1 Cadwell
Sierra Wave (Kennewick, Washington)] and periph-
eral materials were made available for the trial.
On the days of Trial 4 (May 2 and 3, 2013) as
in Trial 3, the clinical neurophysiologists and their
associate technologist occupied separate cubicles
in a large hall. Each subject’s legs were carefully
pre-warmed in warm water, surface temperatures
were measured between evaluations, and limbs
were kept warm between evaluations using specially
fabricated thermal casts. For NC testing, the lower
limbs were introduced through a curtain into the
examining cubicle so that the neurophysiologists
could not identify the patient by sight. In addition,
subjects were asked not to speak to examiners to
maintain masking. Each neurophysiology team
assessed 8 attributes of NC of the left leg of each
of the 22 patients without and with diabetic poly-
neuropathy, made judgments of normality or
abnormality of each attribute assessed, and made
an overall judgment of whether the patient had
electrophysiologic evidence of polyneuropathy. On
the second day, the order of patient assessment
was altered, but each of the 4 clinical neurophysi-
ologists assessed the 8 attributes of NC of the 22
patients by performing the same testing proce-
dures and making the same judgments as those on
day 1. All visible marks of testing were removed
between NC testing of different investigators.
Assessment of Intra- and Interobserver Differences
and Agreement. Wilcoxon signed-rank tests were
used to test for differences between days 1 and 2.
Friedman v2 or Cochran Q tests were used to
assess for interobserver differences. The Krippen-
dorff a was used to assess interobserver agreement.
Because there is considerable evidence that neuro-
physiological functions, such as hearing, vision,
and somatic sensation, increase as linear exponen-
tial functions, and other neurophysiologic func-
tions may increase similarly, we evaluated
interobserver variability using raw neurophysiologic
measurements in addition to broader and perhaps
more clinically meaningful categories of normality
and abnormality. To do this, measured NC data
were transformed into normal deviates from per-
centile values as corrected for applicable physical
variables, and they were also transformed into Neu-
ropathy Impairment Score (NIS) points, namely
attribute values >5th percentile5 0 point (nor-
mal), 5th to >1st5 1 point (abnormal), and
1st5 2 points (highly abnormal). Abnormality of
latencies is expressed in the other tail of the nor-
mal distribution using the same “points from
percentiles” categorization.
Comparison of Judgment of Polyneuropathy within
Trial 4 and between Trials 3 and 4. Cl. NPhys 4
compared the frequency of the clinical neurophysi-
ologists’ judgment of polyneuropathy to transfor-
mations of their measured values to percentiles
and set abnormality of 2 attributes commonly
affected in diabetic polyneuropathy (fibular CMAP
and sural SNAP) at 2.5th percentile.
The frequencies of interobserver differences of
raw measurements of attributes of NC and fre-
quencies of abnormality based on a percentile
abnormality from standard reference values or NIS
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point transformations (from percentiles) were
compared between Trials 3 and 4.
RESULTS
Raw Values of Measured Attributes of NC: Interobserver
Disagreement and Agreement and Intraobserver
Disagreement. Table 1 shows the median and
range of raw values of the 8 measured attributes of
NC assessed in 22 subjects by the 4 groups of clinical
neurophysiologists. Using the Friedman v2 test, stat-
istically significant interobserver differences were
found for 10 of 16 comparisons (shown as shaded
boxes in Table 1). The degree of agreement among
clinical neurophysiologists was assessed using the
Krippendorff a (e.g., values >0.75 were observed for
10 of 16 evaluations).
Using the Wilcoxon signed-rank test, no statisti-
cally significant intraobserver difference was found
between days 1 and 2 (footnote to Table 1). These
results show that, although interobserver differences
were observed commonly, there were no significant
intraobserver differences between days 1 and 2.
Attributes of NC Transformed to NIS Points from
Percentiles (>5th/<95th50; £5th to >1st/‡95th to
<99th51; and £1st/‡99th52) Percentiles Corrected
for Applicable Variables from a Standard Reference
Source [Rochester Diabetic Neuropathy Study—Healthy
Subjects (RDNS-HS)]. Statistically significant inter-
observer disagreement was found for only 3 of 16
comparisons. Using this transformation, in Table 2
agreement among clinical neurophysiologists, as
measured by the Krippendorff a, averaged
0.726 0.19, very similar to the value obtained when
Table 1. Raw values of measured attributes of nerve conduction: interobserver disagreement and agreement (and intraobserver
disagreement*).
Friedman v2 test for
differences among 4 Cl. NPhys
teams
Krippendorff a
(ratio)
Nerve
Day 1 Day 2 Day 1 Day 2 Day 1 Day 2
conduction
attribute
Cl.
NPhys Median Range Median Range v2 P v2 P a
Bootstrap
95% CI a
Bootstrap
95% CI
Fibular
CMAP
(mV)
1 2.0 0.0–8.0 1.6 0.0–8.3 32.02 <0.01 21.77 <0.01 0.75 (0.65–0.85) 0.81 (0.72–0.89)
2 2.0 0.0–8.1 3.3 0.0–8.9
3 1.6 0.0–8.1 1.5 0.0–7.8
4 1.8 0.0–9.1 2.1 0.0–8.4
Fibular
MNCV
(m/s)
1 41.0 35.0–48.0 43.0 35.0–49.0 3.67 0.29 11.00 0.02 0.81
(0.70–0.89)
0.81
(0.76–0.86)2 40.5 30.0–49.0 41.0 33.0–49.0
3 41.0 25.0–50.0 40.0 31.0–50.0
4 40.0 32.0–50.0 40.5 33.0–47.0
Fibular
MNDL
(ms)
1 4.6 3.4–7.9 4.6 3.6–8.0 13.04 <0.01 4.87 0.18 0.87
(0.83–0.91)
0.84
(0.79–0.87)2 4.8 3.7–8.0 4.6 3.8–6.6
3 4.8 4.0–9.0 4.7 3.9–6.7
4 4.8 3.7–10.7 4.6 3.5–8.5
Tibial
CMAP
(mV)
1 4.1 0.0–8.5 3.6 0.0–10.6 20.01 <0.01 20.41 <0.01 0.76
(0.65–0.86)
0.83
(0.75–0.90)2 4.2 0.0–9.2 4.3 0.0–9.5
3 3.7 0.0–9.4 3.9 0.0–8.0
4 4.2 0.0–11.9 4.3 0.0–9.1
Tibial
MNCV
(m/s)
1 41.5 32.0–48.0 41.0 33.0–53.0 2.51 0.47 3.05 0.38 0.59
(0.46–0.71)
0.58
(0.44–0.70)2 41.0 30.0–48.0 40.0 33.0–50.0
3 41.0 34.0–48.0 41.0 31.0–47.0
4 40.0 33.0–52.0 41.0 36.0–49.0
Tibial
MNDL
(ms)
1 4.4 3.5–6.8 4.1 3.7–6.3 31.43 <0.01 31.74 <0.01 0.39
(0.20–0.56)
0.45
(0.29–0.59)2 4.5 3.6–5.8 4.2 3.6–5.8
3 5.0 3.8–8.5 5.0 3.9–6.0
4 4.9 3.8–7.5 4.8 3.7–6.0
Sural
SNAP
(mV)
1 3.5 0.0–9.0 3.5 0.0–10.0 23.83 <0.01 27.44 <0.01 0.62
(0.49–0.74)
0.65
(0.53–0.77)2 5.0 0.0–11.0 4.5 0.0–11.0
3 1.5 0.0–8.0 3.0 0.0–8.0
4 3.0 0.0–9.0 3.0 0.0–11.0
Sural
SNDL
(ms)
1 4.1 3.3–5.0 4.0 3.5–5.3 3.86 0.28 0.68 0.88 0.85
(0.80–0.88)
0.87
(0.83–0.90)2 3.9 3.4–4.8 4.0 3.3–4.7
3 3.9 3.3–5.3 4.0 3.5–5.1
4 4.2 3.3–4.9 4.1 3.3–4.9
*Wilcoxon signed-rank tests were not statistically significant between days 1 and 2.
Shaded boxes represent statistically significant differences among the neurophysiologist results. Shaded boxes indicate p values 0.05.
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measured raw values were compared (previous sub-
section). Values >0.75 were observed 7 of 16 times.
No significant intraobserver difference was
observed between days 1 and 2 (footnote to
Table 2).
Clinical Neurophysiologist Judgment of Abnormality of
Attributes of NC: Interobserver Disagreement and
Agreement and Intraobserver Disagreement. Statisti-
cally significant disagreement of attributes of NC
was observed for 7 of 16 such comparisons (Table
3). The average Krippendorff a among clinical
neurophysiologists for the 8 attributes of NC was
0.656 0.15. High values (i.e., >0.75) were
observed for 5 of 16 comparisons. No intraobserver
difference was found between days 1 and 2 (foot-
note to Table 3).
Judgment of Abnormality of Attributes of NC Using
Defined Percentile Abnormalities (£2.5th/‡97.5th) from
a Standard Reference Source (RDNS-HS). Clinical
neurophysiologist measurements of attributes of
NC were converted to percentiles and declared to
be normal or abnormal by the criterion of 2.5th/
>97.5th based on healthy subject reference values
from the RDNS-HS cohort. Using this criterion,
statistically significant interobserver differences
were observed in 4 of 16 such comparisons (Table
4). If the percentile criterion was changed to
Table 2. Measured attributes of nerve conduction transformed to NIS points* from RDNS-HS† percentiles: interobserver disagreement
and agreement (and intraobserver disagreement‡).
Friedman v2 test for
differences among 4 Cl. NPhys
teams
Krippendorff a
(ratio)
Nerve
Day 1 Day 2 Day 1 Day 2 Day 1 Day 2
conduction
attribute
Cl.
NPhys Median Range Median Range v2 P v2 P a
Bootstrap
95% CI a
Bootstrap
95% CI
Fibular
CMAP
(points:
3 categories)
1 0.0 0.0–2.0 0.0 0.0–2.0 4.71 0.19 3.00 0.39 0.94 (0.89–0.99) 0.99 (0.98–1.00)
2 0.0 0.0–1.0 0.0 0.0–1.0
3 0.0 0.0–2.0 0.0 0.0–2.0
4 0.0 0.0–1.0 0.0 0.0–1.0
Fibular
MNCV
(points:
3 categories)
1 0.0 0.0–2.0 0.0 0.0–2.0 7.60 0.06 3.24 0.36 0.77 (0.69–0.86) 0.79 (0.70–0.87)
2 0.0 0.0–2.0 0.0 0.0–2.0
3 1.0 0.0–2.0 0.0 0.0–2.0
4 0.0 0.0–2.0 0.0 0.0–2.0
Fibular
MNDL
(points:
3 categories)
1 0.0 0.0–2.0 0.0 0.0–2.0 1.29 0.73 3.97 0.26 0.77 (0.63–0.90) 0.67 (0.50–0.82)
2 0.0 0.0–2.0 0.0 0.0–2.0
3 0.0 0.0–2.0 0.0 0.0–2.0
4 0.0 0.0–2.0 0.0 0.0–2.0
Tibial
CMAP
(points:
3 categories)
1 0.0 0.0–2.0 0.0 0.0–1.0 4.00 0.26 6.33 0.10 0.99 (0.98–1.00) 0.94 (0.87–0.99)
2 0.0 0.0–2.0 0.0 0.0–2.0
3 0.0 0.0–2.0 0.0 0.0–2.0
4 0.0 0.0–2.0 0.0 0.0–2.0
Tibial
MNCV
(points:
3 categories)
1 0.0 0.0–2.0 0.0 0.0–2.0 0.86 0.84 2.37 0.50 0.69 (0.59–0.78) 0.54 (0.38–0.69)
2 0.0 0.0–2.0 0.0 0.0–2.0
3 1.0 0.0–2.0 0.0 0.0–2.0
4 0.0 0.0–2.0 0.0 0.0–2.0
Tibial
MNDL
(points:
3 categories)
1 0.0 0.0–2.0 0.0 0.0–2.0 16.10 <0.01 17.94 <0.01 0.31 (0.15–0.47) 0.48 (0.32–0.63)
2 0.0 0.0–2.0 0.0 0.0–2.0
3 1.0 0.0–2.0 1.0 0.0–2.0
4 1.0 0.0–2.0 0.0 0.0–2.0
Sural
SNAP
(points:
3 categories)
1 0.5 0.0–1.0 0.5 0.0–1.0 7.76 0.05 8.59 0.04 0.70 (0.59–0.80) 0.69 (0.58–0.80)
2 0.0 0.0–2.0 0.0 0.0–2.0
3 1.0 0.0–2.0 0.5 0.0–2.0
4 0.0 0.0–2.0 0.0 0.0–2.0
Sural
SNDL
(points:
3 categories)
1 0.0 0.0–2.0 0.0 0.0–2.0 4.13 0.25 3.02 0.39 0.59 (0.42–0.74) 0.73 (0.60–0.85)
2 0.0 0.0–2.0 0.0 0.0–2.0
3 0.0 0.0–2.0 0.0 0.0–2.0
4 0.0 0.0–2.0 0.0 0.0–2.0
*Percentile values corrected to NIS points: >5th50; 5th to >1st5 1; and 1st5 2 points, and similar conversions if values are in the upper tail of the
distribution (e.g., motor nerve distal latencies).
†Rochester Diabetic Neuropathy-Healthy Subjects (RDNS-HS) used to produce standard reference values.
‡Wilcoxon signed-rank tests were not statistically significant between days 1 and 2.
Shaded boxes represent statistically significant differences among neurophysiologist results. Shaded boxes indicate p values 0.05.
Cl. NPhys Trial 4 MUSCLE & NERVE December 2014 903
5th/>95th percentile, interobserver differences
among clinical neurophysiologists were found in 3
of 16 such comparisons. When the criterion was
changed to 1st/>99th percentile, no significant
interobserver disagreement was found, but this lat-
ter comparison may be invalid because too few
patients had this degree of abnormality to allow
valid testing.
The agreement among investigators using the
Krippendorff a was 0.676 0.19. No intraobserver
difference was observed between days 1 and 2
(footnote to Table 4).
Statistically Significant Interobserver Difference of
Attributes of NC in Trials 3 and 4. Using the desig-
nation of D for significant interobserver differen-
ces for both days, AD for significant difference on
only 1 day, and A (agreement) for no difference
for either day, it was possible to compare the fre-
quency of interobserver disagreement between Tri-
als 3 and 4 (Table 5). Using measured raw values,
agreement was observed in only 1 of 16 observa-
tions in Trial 3 and 6 of 16 observations in Trial 4.
For normal deviates the frequencies were: 2 of 16
for Trial 3 and 6 of 16 for Trial 4. For NIS points
from percentiles the ratios were 7 of 16 and 13 of
16, respectively. The data clearly imply improved
interobserver agreement in Trial 4 when compared
with Trial 3.
Clinical Neurophysiologist Judgment of Neurophysiologic
Diagnosis of Polyneuropathy versus Judgment Based on
Percentile Abnormality of Fibular MNCV and Sural SNAP
Using a Standard Reference Source (RDNS-HS). Statisti-
cally significant disagreement was shown for 1 day
for each criterion used to diagnose polyneuropathy
Table 3. Clinical neurophysiologists’ judgment of abnormality of attributes of nerve conduction: interobserver disagreement and agree-
ment (and intraobserver disagreement*).
Number (%) of 24
Cochran Q test for
differences among 4 Cl.
NPhys teams
Krippendorff a
(ordinal)
Nerve
Day 1 Day 2 Day 1 Day 2 Day 1 Day 2
conduction
attribute
Cl.
NPhys Normal Abnormal Normal Abnormal Q P Q P a
Bootstrap
95% CI a
Bootstrap
95% CI
Fibular
CMAP
abnormality
(Dr.’s judgment)
1 11 (50.0) 11 (50.0) 11 (50.0) 11 (50.0) 4.80 0.19 4.71 0.19 0.85 (0.74–0.94) 0.90 (0.80–0.98)
2 13 (59.1) 9 (40.9) 12 (54.5) 10 (45.5)
3 11 (50.0) 11 (50.0) 10 (45.5) 12 (54.5)
4 13 (59.1) 9 (40.9) 12 (54.5) 10 (45.5)
Fibular
MNCV
abnormality
(Dr.’s judgment)
1 13 (59.1) 9 (40.9) 14 (63.6) 8 (36.4) 13.55 <0.01 13.80 <0.01 0.55 (0.39–0.72) 0.62 (0.46–0.76)
2 8 (36.4) 14 (63.6) 8 (36.4) 14 (63.6)
3 15 (68.2) 7 (31.8) 12 (54.5) 10 (45.5)
4 15 (68.2) 7 (31.8) 15 (68.2) 7 (31.8)
Fibular
MNDL
abnormality
(Dr.’s judgment)
1 17 (77.3) 5 (22.7) 18 (81.8) 4 (18.2) 1.94 0.58 2.40 0.49 0.59 (0.37–0.78) 0.75 (0.57–0.90)
2 18 (81.8) 4 (18.2) 19 (86.4) 3 (13.6)
3 17 (77.3) 5 (22.7) 17 (77.3) 5 (22.7)
4 19 (86.4) 3 (13.6) 18 (81.8) 4 (18.2)
Tibial
CMAP
abnormality
(Dr.’s judgment)
1 13 (59.1) 8 (36.4) 14 (63.6) 8 (36.4) 6.00 0.11 6.00 0.11 0.83 (0.72–0.93) 0.90 (0.80–0.98)
2 13 (59.1) 9 (40.9) 14 (63.6) 8 (36.4)
3 15 (68.2) 7 (31.8) 14 (63.6) 8 (36.4)
4 16 (72.7) 6 (27.3) 16 (72.7) 6 (27.3)
Tibial
MNCV
abnormality
(Dr.’s judgment)
1 13 (59.1) 8 (36.4) 17 (77.3) 5 (22.7) 6.65 0.08 8.50 0.04 0.59 (0.42–0.75) 0.52 (0.31–0.71)
2 13 (59.1) 9 (40.9) 13 (59.1) 9 (40.9)
3 17 (77.3) 5 (22.7) 18 (81.8) 4 (18.2)
4 17 (77.3) 5 (22.7) 18 (81.8) 4 (18.2)
Tibial
MNDL
abnormality
(Dr.’s judgment)
1 19 (86.4) 2 (9.1) 19 (86.4) 3 (13.6) 0.69 0.88 4.70 0.19 0.47 (0.15–0.79) 0.64 (0.32–0.93)
2 19 (86.4) 3 (13.6) 20 (90.9) 2 (9.1)
3 20 (90.9) 2 (9.1) 21 (95.5) 1 (4.5)
4 20 (90.9) 2 (9.1) 21 (95.5) 1 (4.5)
Sural
SNAP
abnormality
(Dr.’s judgment)
1 9 (40.9) 13 (59.1) 7 (31.8) 15 (68.2) 12.78 <0.01 14.38 <0.01 0.60 (0.43–0.74) 0.56 (0.40–0.72)
2 15 (68.2) 7 (31.8) 14 (63.6) 8 (36.4)
3 8 (36.4) 14 (63.6) 7 (31.8) 15 (68.2)
4 11 (50.0) 11 (50.0) 11 (50.0) 11 (50.0)
Sural
SNDL
abnormality
(Dr.’s judgment)
1 12 (54.5) 10 (45.5) 13 (59.1) 9 (40.9) 14.82 <0.01 17.40 <0.01 0.50 (0.32–0.66) 0.46 (0.29–0.63)
2 17 (77.3) 5 (22.7) 18 (81.8) 4 (18.2)
3 8 (36.4) 14 (63.6) 8 (36.4) 14 (63.6)
4 12 (54.5) 10 (45.5) 12 (54.5) 10 (45.5)
*Wilcoxon signed-rank tests were not statistically significant between days 1 and 2.
Shaded boxes represent statistically significant differences among neurophysiologist results. Shaded boxes indicate p values 0.05.
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[i.e., clinical neurophysiologist judgment as com-
pared with transformation of their measured values
to percentiles and declaring abnormality when fib-
ular MNCV and sural SNAP were 2.5th percen-
tiles based on healthy subject reference values
from the RDNS-HS). The degree of agreement
among investigators was considerably higher using
the latter approach (Table 6).
DISCUSSION
Attributes of NC are useful measurements for
detection, characterization, and following the
course of peripheral neuropathy. They are therefore
useful in medical practice, epidemiologic surveys,
and therapeutic trials.3–12 By contrast, because they
are physiological measures, they have less value for
quantifying the clinical severity of muscle weakness
or large-fiber sensory loss, and they typically have no
value for characterizing or quantifying small sensory
or autonomic fiber dysfunction. Therefore, attrib-
utes of NC are generally considered to be surrogate
measures of polyneuropathy.13
Because attributes of NC are quantitative assess-
ments that provide numeric values, it may be
assumed that they are reliable indicators of abnor-
mality and have no or low intra- or interrater vari-
ability. However, these assumptions are incorrect.
Proficiency (accuracy and no or low intra- and
interobserver variability) is heavily dependent on
how NCs are performed, assessed, and interpreted.
NCs can (and may be) performed and interpreted
inaccurately.
Table 4. Judgment of abnormality from use of defined percentile abnormality (2.5th/>97.5th) and standard reference values* on attrib-
utes of nerve conduction: interobserver disagreement and agreement (and intraobserver disagreement†).
Number (%) of 24
Cochran Q test for
differences among 4 Cl.
NPhys teams
Krippendorff a
(ordinal)
Nerve
Day 1 Day 2 Day 1 Day 2 Day 1 Day 2
conduction
attribute
Cl.
NPhys Normal Abnormal Normal Abnormal Q P Q P a
Bootstrap
95% CI a
Bootstrap
95% CI
Fibular
CMAP
abnormality
(ND 2.5th)
1 16 (72.7) 4 (18.2) 17 (77.3) 5 (22.7) 7.60 0.06 3.00 0.39 0.49 (0.23–0.71) 0.71 (0.52–0.86)
2 20 (90.9) 1 (4.5) 18 (81.8) 2 (9.1)
3 17 (77.3) 5 (22.7) 17 (77.3) 5 (22.7)
4 20 (90.9) 2 (9.1) 19 (86.4) 3 (13.6)
Fibular
MNCV
abnormality
(ND 2.5th)
1 13 (59.1) 5 (22.7) 15 (68.2) 4 (18.2) 5.23 0.16 3.00 0.39 0.78 (0.63– 0.90) 0.94 (0.85– 1.00)
2 13 (59.1) 7 (31.8) 14 (63.6) 5 (22.7)
3 14 (63.6) 5 (22.7) 13 (59.1) 6 (27.3)
4 17 (77.3) 4 (18.2) 14 (63.6) 6 (27.3)
Fibular
MNDL
abnormality
(ND >97.5th)
1 18 (81.8) 2 (9.1) 19 (86.4) 1 (4.5) 2.40 0.49 4.71 0.19 0.54 (0.24–0.78) 0.68 (0.41–0.89)
2 19 (86.4) 1 (4.5) 17 (77.3) 2 (9.1)
3 16 (72.7) 3 (13.6) 17 (77.3) 2 (9.1)
4 18 (81.8) 3 (13.6) 17 (77.3) 3 (13.6)
Tibial
CMAP
abnormality
(ND 2.5th)
1 19 (86.4) 2 (9.1) 18 (81.8) 2 (9.1) 3.00 0.39 – – 0.90 (0.73–1.00) 1.00 (1.00–1.00)
2 19 (86.4) 3 (13.6) 19 (86.4) 3 (13.6)
3 19 (86.4) 3 (13.6) 19 (86.4) 3 (13.6)
4 19 (86.4) 3 (13.6) 19 (86.4) 3 (13.6)
Tibial
MNCV
abnormality
(ND 2.5th)
1 14 (63.6) 6 (27.3) 15 (68.2) 4 (18.2) 1.84 0.61 2.61 0.46 0.43 (0.24–0.61) 0.36 (0.15–0.58)
2 16 (72.7) 5 (22.7) 17 (77.3) 4 (18.2)
3 13 (59.1) 6 (27.3) 13 (59.1) 7 (31.8)
4 13 (59.1) 8 (36.4) 14 (63.6) 7 (31.8)
Tibial
MNDL
abnormality
(ND 97.5th)
1 18 (81.8) 2 (9.1) 16 (72.7) 3 (13.6) 8.59 0.04 11.33 0.01 0.35 (0.10–0.58) 0.58 (0.37–0.77)
2 18 (81.8) 3 (13.6) 19 (86.4) 2 (9.1)
3 14 (63.6) 7 (31.8) 14 (63.6) 7 (31.8)
4 14 (63.6) 7 (31.8) 15 (68.2) 6 (27.3)
Sural
SNAP
abnormality
(ND 2.5th)
1 12 (54.5) 10 (45.5) 14 (63.6) 8 (36.4) 9.27 0.03 12.60 <0.01 0.65 (0.50– 0.79) 0.68 (0.54–0.81)
2 16 (72.7) 6 (27.3) 17 (77.3) 5 (22.7)
3 11 (50.0) 11 (50.0) 11 (50.0) 11 (50.0)
4 15 (68.2) 7 (31.8) 12 (54.5) 10 (45.5)
Sural
SNDL
abnormality
(ND >97.5th)
1 14 (63.6) 3 (13.6) 15 (68.2) 2 (9.1) 3.67 0.30 – – 0.74 (0.53–0.91) 0.87 (0.70–1.00)
2 15 (68.2) 2 (9.1) 15 (68.2) 3 (13.6)
3 12 (54.5) 1 (4.5) 12 (54.5) 2 (9.1)
4 12 (54.5) 4 (18.2) 11 (50.0) 2 (9.1)
ND, normal deviate.
*Rochester Diabetic Neuropathy Healthy Subject Cohort (RDNS-HS) used to produce standard reference values.
†Wilcoxon signed-rank tests were not statistically significant between days 1 and 2.
Shaded boxes represent statistically significant differences among neurophysiologist results. Shaded boxes indicate p values 0.05.
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The question of NC proficiency has been tested
directly in 2 previous trials utilizing expert clinical
neurophysiologists.2,14 Neither trial identified sig-
nificant intraobserver differences in their NC
assessments, but they both found significant inter-
observer differences. Also, some of these interob-
server differences were of sufficient magnitude to
make it of concern, especially for use in therapeu-
tic trials. The degree of interobserver variability in
the 2 trials was surprising, because, in the first,
clinical neurophysiologists came from the same
medical center and, in the second, investigators
had been trained by physicians at the same center.
Trial 4 addressed 2 questions: (1) Could inter-
observer differences of measured NC attributes be
reduced or eliminated by pretrial agreement to
use exactly the same techniques of testing? (2)
Could judgment of abnormality of individual
attributes of NC and clinical neurophysiologic
diagnosis of polyneuropathy be improved by use
of common reference standards and setting
abnormality by defined percentile levels of abnor-
mality? Interobserver differences in assessed meas-
ured attributes of NC were less frequent in Trial 4
than in Trial 3. Presumably this decrease related
to use of highly standardized techniques of NC
assessment. However, one should note that inter-
observer disagreement was not eliminated. There
were still differences in measured attributes of NC
abnormality despite rigorous attempts to eliminate
Table 5. Statistically significant* interobserver differences for both days 1 and 2 (D), for only 1 of the 2 days (AD) and for neither day (A)
in Cl. NPhs Trials 3 and 4
Trial
NCs measured units
NCs expressed as
normal deviates†
(from percentiles)
NCs expressed as
NIS points (3
categories)‡
Nerve conduction attribute 3 4 3 4 3 4
Fibular CMAP D D D D A A
Fibular MNCV AD AD A AD A A
Fibular MNDL D AD D AD D A
Tibial CMAP D D D D D A
Tibial MNCV D A D A D A
Tibial MNDL D D D D AD D
Sural SNAP D D D D AD AD
Sural SNDL D A D A AD A
McNemar S 3.57 2.67 3.60
exact test P 0.1250 0.2188 0.1094
*Using the Friedman v2 test.
†Normal deviates-from percentile values of measured values corrected for applicable values (e.g., age, height, and others).
‡NIS points-3 percentile categories: 1st percentile5 2; >1st 5th percentile5 1; >5th percentile50. If the abnormality is in the other tail of the normal
distribution, the order is reversed.
Table 6. Clinical neurophysiologists’ judgment and standard percentile/reference values for diagnosis of polyneuropathy: interobserver
disagreement and agreement (and intraobserver disagreement*).
Number (%) of 24
Cochran Q test for differ-
ences among 4 Cl. NPhys
teams
Krippendorff a
(ordinal)
Day 1 Day 2 Day 1 Day 2 Day 1 Day 2
Nerve
conduction
attribute
Cl.
NPhys Normal Abnormal Normal Abnormal Q P Q P a
Bootstrap
95% CI a
Bootstrap
95% CI
Neuropathy
(Dr.’s judgment)
1 9 (40.9) 13 (59.1) 7 (31.8) 15 (68.2) 6.00 0.11 11.88 <0.01 0.73 (0.60–0.86) 0.63 (0.47–0.76)
2 12 (54.5) 10 (45.5) 13 (59.1) 9 (40.9)
3 13 (59.1) 9 (40.9) 13 (59.1) 9 (40.9)
4 12 (54.5) 10 (45.5) 12 (54.5) 10 (45.5)
Neuropathy
(R fibular CMAP
and sural
SNAP 2.5th)
1 12 (54.5) 10 (45.5) 13 (59.1) 9 (40.9) 9.00 0.03 5.18 0.16 0.86 (0.76–0.96) 0.83 (0.71–0.94)
2 15 (68.2) 7 (31.8) 15 (68.2) 7 (31.8)
3 12 (54.5) 10 (45.5) 12 (54.5) 10 (45.5)
4 12 (54.5) 10 (45.5) 13 (59.1) 9 (40.9)
*Wilcoxon signed-rank tests were not statistically significant between days 1 and 2.
Shaded boxes represent statistically significant differences among neurophysiologist’s results. Shaded boxes indicate p values 0.05.
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them. The fact that intraobserver differences were
not found yet interobserver differences were
found in all 3 trials suggests that the NC techni-
ques are being performed reproducibly by individ-
ual clinical neurophysiologists. However, Trial 4
results also suggest that subtle differences of
technique remain despite pre-instruction and
agreement on techniques of test performance.
Small differences in the EMG instrumentation
used may conceivably account for some of the dif-
ferences observed, but they probably would not
explain difference of selective abnormality of
some attributes of NC.
Are the observed interobserver differences of
sufficient magnitude to be of concern for conduct
of medical practice or therapeutic trials? For use
in medical practice, the small differences observed
do not appear to be meaningful clinically (see
later), although accurate assessment of NC results
with small interobserver differences remains a goal
for conduct of both medical practice and thera-
peutic trials. For therapeutic trials, even very small
interobserver differences are of concern, because
they decrease the statistical power of a study and
may affect the success of a trial. Therefore, our
studies support the conclusions of earlier studies2
that the most optimal therapeutic trial perform-
ance results when the same clinical neurophysiolo-
gists perform all serial NCs on a given subject.
This trial also demonstrates the value of using
common reference values, setting abnormality,
and the use of an agreed-upon percentile abnor-
mal value.15 Interobserver disagreement of judg-
ment of abnormality of individual attributes of
NC was reduced using common reference values
and defining their abnormality by a given percen-
tile as compared with individual clinical neuro-
physiologists’ judgment. The latter judgments may
relate to different reference values among medical
centers. These data provide a rationale for use of
common reference standards and defined percen-
tile abnormality among EMG laboratories.
Could the choice of subjects explain the
observed significant interobserver differences of
measured attributes of NC in the Cl. NPhys 3 and
4 Trials? It seems unlikely that the somewhat
advanced age of subjects would account for the
demonstrated interobserver differences of meas-
ured attributes of NC. Conceivably it could have
affected judgment of abnormality for individual
attributes of NC assessed and for judgment of poly-
neuropathy. The patients’ median age of 70 years
required the electrophysiologists to distinguish
changes related to “normal” aging from those due
to diabetes. This proved challenging, presumably
because of limited normative data available to
investigators for subjects of advanced age and
because the lower limit of normal for some attrib-
utes approaches the response detection limit. In
this context, median values for sural SNAP ampli-
tudes ranging from 2 to 5 lV represented signifi-
cant intraobserver differences, but are unlikely to
represent a physiologically important difference,
emphasizing the use of broader categories of NC
abnormality based on standard reference values
corrected for applicable variables.
This trial (Cl. NPhys 4) is the part of a series of
trials by our group aimed at assessing the profi-
ciency of neuropathy signs (Trials 1 and 2), attrib-
utes of NC (Trial 3 and this trial), quantitative
sensation testing (Trial 5), and perhaps
others.14,16,17
Proficiency testing is now expected in the
assessment of most laboratory tests. Such profi-
ciency testing has not been required of clinical
assessments of neuropathy symptoms and signs or
of clinical neurophysiologic tests, presumably due
to the impracticality. For laboratory proficiency
testing, it is possible to send a small sample of
serum or tissue to a reference or multiple refer-
ence laboratories, which can be done on multiple
occasions and on a continuing basis. The same
proficiency procedures cannot be followed for
assessment of patients’ examinations. However, it
is possible, as shown in our Cl. NPhys trials, to do
proficiency testing occasionally to assess critically
the proficiency of physician clinical or neurophysi-
ology test assessments.
APPENDIX
Additional Cl. NPhys Trial 4 Investigators. Additional
members of the Coordinating Committee: P. James B.
Dyck, MD, and Phillip A. Low, MD (Department of
Neurology, Mayo Clinic, Rochester, MN, USA).
Study neurologists and diabetologists: Henning Ander-
sen, MD (Aarhus University Hospital, Aarhus, Den-
mark); John D. England, MD (Department of
Neurology, Louisiana State University, New Orle-
ans, LA, USA); Gareth Llewelyn, MD (University
Hospital of Wales, Cardiff, Wales, UK); Michelle L.
Mauermann, MD (Department of Neurology, Mayo
Clinic, Rochester, MN); Dinesh Selvarajah, MD
(Royal Hallamshire Hospital, Sheffield, UK); Wolf-
gang Singer, MD (Department of Neurology, Mayo
Clinic, Rochester, MN); A. Gordon Smith, MD
(University of Utah, Salt Lake City, UT); Solomon
Tesfaye, MD (Royal Hallamshire Hospital, Shef-
field, UK); and Adrian Vella, MD (Division of
Endocrinology, Diabetes, Metabolism and Nutri-
tion, Mayo Clinic, Rochester, MN, USA).
The authors thank Mary Lou Hunziker, Department of Neurology,
Mayo Clinic, for preparation of the manuscript.
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